Understand the source comparison
Ipamorelin Fat Loss Complete Guide 2026: Comparison Table
Before selecting a peptide protocol, understanding how different growth hormone secretagogues compare across selectivity, side effect profiles, and practical dosing helps researchers design studies that align with specific metabolic endpoints. Ipamorelin Selec
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before selecting a peptide protocol, understanding how different growth hormone secretagogues compare across selectivity, side effect profiles, and practical dosing helps researchers design studies that align with specific metabolic endpoints.
- Ipamorelin
- Selective GHS-R1a agonist
- No elevation
- 200–300mcg 1–3×/day
- GH release without cortisol or appetite stimulation
- Best choice when cortisol elevation or increased hunger would confound results. Cleanest GH pulse profile
- GHRP-2
- Non-selective ghrelin mimetic
- Moderate cortisol increase
- 100–300mcg 2–3×/day
- Stronger GH pulse than ipamorelin, some appetite increase
- Higher peak GH but cortisol co-release limits use in studies focused purely on lipolysis
- GHRP-6
- Moderate cortisol + prolactin increase
- Strongest appetite stimulation, robust GH release
- Useful in muscle-gain protocols but appetite surge works against fat-loss objectives
- MK-677 (Ibutamoren)
- Oral GHS-R1a agonist
- No cortisol elevation
- 10–25mg once daily (oral)
- Sustained GH/IGF-1 elevation, no injections required
- Convenient oral dosing but continuous receptor activation risks desensitisation; less pulsatile than ipamorelin
- CJC-1295 (DAC)
- GHRH analogue with extended half-life
- No direct effect
- 2mg once weekly (subcutaneous)
- Amplifies endogenous GH pulses for 7–10 days per dose
- Often stacked with ipamorelin to increase pulse amplitude. Not typically used alone for fat loss